Phoenixin-20: brain peptide that drives reproductive hormones
A natural brain signaling peptide that triggers the release of reproductive hormones; also studied for reducing anxiety in animals; experimental, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
Phoenixin is a neuropeptide discovered in 2013, encoded by the SMIM20 gene — a gene previously thought to produce only a transmembrane structural protein with no signaling role. Proteolytic processing of the SMIM20 gene product yields two amidated neuropeptide forms: phoenixin-14 (14 aa) and phoenixin-20 (20 aa, the longer isoform stored here). Its receptor is GPR173 (also designated SREB3), a previously orphan GPCR expressed mainly in the hypothalamus and pituitary. Phoenixin's primary characterized function is stimulation of GnRH (gonadotropin-releasing hormone) release, placing it in the reproductive neuroendocrine axis; additional roles in anxiety modulation, pain, and energy metabolism have been proposed but are less thoroughly characterized. Phoenixin has no approved clinical use and remains a research-stage neuropeptide.
The stored sequence DVQPPGLKVWSDPFGKSVPD (20 aa) represents the canonical human phoenixin-20; the native mature form is C-terminally amidated at Pro²⁰ — that amide is not reflected in the stored one-letter sequence. A shorter 14-aa isoform (phoenixin-14) is also described in the discovery paper (Yosten and colleagues 2013) but is not stored on this card.
History
Phoenixin was identified in 2013 by Gina Yosten, Willis Samson, and colleagues at Saint Louis University, using a bioinformatics screen of the mouse hypothalamic transcriptome to identify putative novel neuropeptides. The strategy relied on finding transcripts encoding small proteins with prohormone features: signal peptides, dibasic cleavage sites, and C-terminal Gly residues indicative of amidation. The SMIM20 transcript, previously annotated only as a structural membrane protein, was found to encode a precursor with these features, and mass spectrometry confirmed the presence of two amidated processed forms (phoenixin-14 and phoenixin-20) in rodent hypothalamic extracts.
The 2013 discovery paper in the Journal of Neuroendocrinology (Yosten and colleagues 2013) demonstrated that intracerebroventricular injection of phoenixin-20 in female rats advanced the timing of the LH surge (the preovulatory gonadotropin pulse that triggers ovulation), and that immunoneutralization of phoenixin delayed puberty onset — establishing a functional role in reproductive neuroendocrinology.
In the same year, Lyu and colleagues at Drexel University published a complementary paper in Neuroscience (Lyu and colleagues 2013) characterizing phoenixin expression in rodent sensory ganglia and the dorsal horn, suggesting additional roles in sensory and nociceptive processing beyond the reproductive axis.
The name "phoenixin" was coined by the Yosten group, reportedly inspired by the mythological phoenix — reflecting the idea of a new peptide rising from a gene previously thought to be non-regulatory. GPR173 was confirmed as the primary phoenixin receptor through heterologous expression and peptide competition assays.
What it does
GnRH stimulation and reproductive axis regulation: Phoenixin's best-characterized action is stimulation of GnRH release from hypothalamic neurons, which drives pulsatile LH and FSH secretion from the anterior pituitary, ultimately regulating gonadal steroidogenesis and gametogenesis. In rat models, intracerebroventricular phoenixin-20 accelerated the LH surge, and immunoneutralization of endogenous phoenixin delayed puberty onset in female rats (Yosten and colleagues 2013). Phoenixin neurons in the hypothalamus receive input from kisspeptin-containing neurons, placing phoenixin in a signaling network alongside the established kisspeptin/GnRH axis.
Anxiolytic effects: Several studies have reported that peripheral or central administration of phoenixin-20 reduces anxiety-like behaviors in rodent models (open field test, elevated plus maze). The anxiolytic effect may be mediated through GPR173 in limbic brain regions, potentially involving modulation of GABAergic and glutamatergic transmission. The mechanistic pathway connecting phoenixin to anxiety circuits is not fully established, but is consistent with phoenixin's expression in limbic structures including the amygdala and hippocampus.
Pain modulation: Phoenixin expression in dorsal root ganglia and the dorsal horn, along with GPR173 expression in nociceptive pathways, suggests a role in pain signal processing (Lyu and colleagues 2013). Phoenixin-14 has been reported to modulate inflammatory pain in rodent models. The direction of effect and the mechanism remain under investigation.
Metabolic and energy regulation: Phoenixin expression changes in response to dietary manipulation, obesity, and metabolic interventions. Valsamakis and colleagues (2021) reviewed evidence linking high-fat diet to upregulated hypothalamic phoenixin expression and proposed that phoenixin's GnRH-stimulatory effects may partly account for the earlier puberty timing seen in obesity models. Phoenixin's role in energy homeostasis may be secondary to its effects on the reproductive axis, where energy status and reproductive function are tightly coupled.
Cardiovascular effects: Peripheral phoenixin administration has been reported to affect blood pressure and heart rate in rodent models, though the magnitude and direction of effects have been variable across studies.
Evidence
- Discovery and reproductive axis characterization. Yosten and colleagues (2013) identified phoenixin through bioinformatics screening of the mouse hypothalamic transcriptome, confirmed the 14-aa and 20-aa amidated forms by mass spectrometry in hypothalamic tissue, identified GPR173 as the receptor by orphan deorphanization pharmacology, and demonstrated that ICV phoenixin-20 in female rats advanced the timing of the LH surge by 3–4 hours. Immunoneutralization of phoenixin with a specific antiserum delayed pubertal timing in female rats. (Journal of Neuroendocrinology, 2013)
- Expression in sensory ganglia and nociceptive circuits. Lyu and colleagues (2013) demonstrated phoenixin immunoreactivity in rat sensory ganglia (dorsal root and trigeminal ganglia) and the dorsal horn, co-expressed with established neuropeptides including substance P. Mass spectrometry confirmed phoenixin-14 and phoenixin-20 in sensory ganglia tissue extracts, and peripheral inflammation altered phoenixin expression in dorsal root ganglion neurons. (Neuroscience, 2013)
- Phoenixin in diet-induced hypothalamic inflammation and precocious puberty. Valsamakis and colleagues (2021) reviewed evidence linking high-fat and high-glycaemic-index diet to hypothalamic inflammation and microglial activation, and proposed phoenixin as a mediating factor in accelerated puberty onset. The review integrated data on phoenixin's interactions with the kisspeptin-GnRH axis and leptin signaling in metabolic and obesity models. (Nutrients, 2021)
Myths and misconceptions
- "Phoenixin is related to the phoenix protein (BIRC5/survivin) or Phoenix syndrome." Phoenixin the neuropeptide has no connection to BIRC5/survivin (an inhibitor-of-apoptosis protein) or to the term "phoenix syndrome" (a vasospasm-related medical phenomenon). The naming is mythological in inspiration, not biochemical.
- "Phoenixin is primarily a female hormone." While phoenixin's initial characterization focused on female rodent reproductive timing, phoenixin and GPR173 are expressed in both male and female hypothalamus, pituitary, and gonads. Male reproductive function and testosterone-related endpoints have been studied under phoenixin regulation as well, though with less published data than the female reproductive studies.
- "Phoenixin's anxiolytic effects mean it's related to benzodiazepines or GABA-A modulation." Phoenixin's anxiolytic-like effects in rodent models are mediated through GPR173, a GPCR, not through GABA-A receptor modulation. While phoenixin may influence GABAergic tone indirectly through limbic circuit interactions, its pharmacological mechanism is fundamentally different from classical anxiolytics. The rodent anxiolytic data come from a small number of studies and should not be extrapolated to suggest a benzodiazepine-like clinical effect.
Common questions
Q: How does phoenixin relate to kisspeptin in reproductive neuroendocrinology? A: Both phoenixin and kisspeptin stimulate GnRH release, but they are structurally unrelated, encoded by different genes, and act through different receptors (GPR173 for phoenixin; KISS1R/GPR54 for kisspeptin). Their signaling likely converges at GnRH neurons in the arcuate nucleus and preoptic area of the hypothalamus. Kisspeptin is considerably better characterized and has progressed to clinical testing (in ovarian stimulation and hypothalamic amenorrhea), while phoenixin remains research-stage. The two systems may have different sensitivity to metabolic and steroid hormone feedback, suggesting complementary rather than redundant roles.
Q: What is the significance of phoenixin being encoded by SMIM20, originally thought to be a non-signaling gene? A: This discovery has methodological implications: it demonstrates that bioinformatics screening of annotated genomes can still yield novel neuropeptides from genes assigned non-regulatory functions. SMIM20 was categorized as encoding a small integral membrane protein, indicating membrane topology rather than signaling activity. The phoenixin discovery showed that the full SMIM20 transcript also encodes a soluble, amidated, and secreted neuropeptide. This is consistent with the broader phenomenon of multi-functional gene products in the nervous system and suggests that other SMIM genes might similarly encode cryptic signaling peptides.
Q: Is phoenixin being developed as a fertility treatment? A: As of 2026, phoenixin is not in clinical development as a fertility treatment. Its GnRH-stimulatory profile is conceptually interesting for conditions of hypothalamic hypogonadism (where kisspeptin is already in trials), but phoenixin-20's short in vivo stability, uncertain receptor subtype selectivity, and limited characterization in human physiology mean that clinical translation is at an early preclinical stage. One registered observational study has measured blood phoenixin-20 levels as a secondary biomarker endpoint after bariatric surgery, reflecting emerging interest in phoenixin as a metabolic biomarker rather than as a therapeutic agent.
Related peptides
- Kisspeptin-10 — the best-characterized hypothalamic GnRH-stimulating neuropeptide; shares phoenixin's functional role in reproductive neuroendocrinology but acts through a different receptor (KISS1R/GPR54); much further along in clinical translation
- Vasopressin — another hypothalamic neuropeptide with defined receptor pharmacology and clinical applications, illustrating what a well-characterized peptide from the same anatomical origin looks like pharmacologically
- Cortistatin-14 — another research-stage endogenous neuropeptide with no approved clinical use, demonstrating the pattern of neuropeptide biology that remains preclinical despite scientific interest
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the natural, chemically complete form of phoenixin-20 bind its receptor far more tightly than lab-made versions that skip the final modification?
If true, decades of lab results using the incomplete peptide could be systematically underestimating how potent this hormone is. Correcting this could open a clearer path to fertility drugs that tap into this signaling pathway.
Does phoenixin-20 work by tuning the pulse-generator neurons that sit one step above the hormone-releasing neurons in the brain?
If phoenixin-20 works at this upstream relay point, it could become a new tool for restoring normal hormone cycles in women with conditions like hypothalamic amenorrhea or PCOS, offering a different and possibly gentler target than current treatments.
Could phoenixin-20 reverse the blunted pituitary response that sometimes derails IVF cycles?
If true, adding a phoenixin-20 analogue to IVF protocols could improve outcomes for patients who respond poorly to standard stimulation, potentially increasing live birth rates without raising GnRH doses and their side effects.
Can phoenixin-20 calm anxiety by acting in the emotional part of the brain, completely independently of its effects on reproductive hormones?
If confirmed, this could lead to a new class of anxiety drugs that work through an entirely fresh mechanism, offering an alternative for patients who cannot tolerate current treatments or who need a drug that does not interfere with their reproductive health.
Are the two proline amino acids near the start of phoenixin-20 acting like a hinge that positions the rest of the peptide correctly to activate its receptor?
If this structural hinge is confirmed, scientists could build shorter, more stable drug-like molecules that mimic only the active core of phoenixin-20, making it far easier and cheaper to develop drugs targeting this hormone pathway.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.43170565366744995 | openfold3-mlx |
| ranking score | 0.52972012758255 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.857 | global PDE — lower = better |
| disorder | 0.054 | fraction disordered |
| chain pair ipTM (A, B) | 0.432 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 662s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep04483,
sequence = {DVQPPGLKVWSDPFGKSVPD},
target = {gpr173},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}